Services
Company
Legal and Governance
Publication Library / Publications
Economic assessment of delaying insulin treatment through the use of newer anti-diabetic agents, dapagliflozin (Forxiga®) and exenatide (Bydureon®), both as add-on to metformin; a cost-effectiveness analysis from a Uk NHS perspective
No abstract available
Authors
M Charokopou, H Vioix, B G Verheggen, D Maddocks, T Bratt, D Franks
Journal
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Therapeutic Area
Endocrinology and metabolism
Center of Excellence
Health Economic Modeling & Meta-analysis
Year
2014
Read full article